Skip to main content

Clinical Trials Using Pacritinib

Review the clinical trials studying pacritinib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-14 of 14

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
Status: Active
Location: 5 locations
A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Status: Active
Location: 4 locations
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
Status: Active
Location: 5 locations
Pacritinib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
Status: Active
Location: 4 locations
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Active
Location: 2 locations
Pacritinib for the Treatment of Relapsed or Refractory Waldenström Macroglobulinemia
Status: Active
Location: 2 locations
Talazoparib in Combination with Pacritinib for the Treatment of Patients with Myeloproliferative Neoplasms Unresponsive to Frontline JAK2 Inhibition
Status: Active
Location: 2 locations
Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Decitabine with Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Bemcentinib and Pacritinib for Treating Patients with Locally Advanced and/or Metastatic, Recurrent or Refractory Lung Cancer
Status: Active
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Pacritinib in Combination with Azacitidine for the Treatment of Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Pacritinib for the Treatment of Patients with VEXAS Syndrome
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Pacritinib in Combination with a BTK Inhibitor for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California